Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices dip after 5-day winning streak; set for weekly surge on Iran conflict Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock By Insider Trading Published 03/05/2026, 10:52 PM Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock 0 CYTK -0.13% Andrew Callos, Executive Vice President and Chief Commercial Officer at Cytokinetics INC (NASDAQ:CYTK) , sold a total of 26,000 shares of common stock on March 5, 2026, for approximately $1.6 million. The sales were executed in two tranches, with prices ranging from $61.87 to $61.88 per share. The stock currently trades at $62.19, up 44% over the past year, though InvestingPro analysis suggests the shares remain undervalued with a Fair Value of $71.12. On the same day, Callos also exercised options to acquire a total of 26,000 shares of Cytokinetics common stock. These transactions involved two separate option grants. 11,000 shares were acquired at an exercise price of $39.13, and 15,000 shares were acquired at an exercise price of $23.26, for a total value of $779330. Following these transactions, Callos directly owns 50,440 shares of Cytokinetics INC. While the company remains unprofitable with an EPS of -$6.54, analysts maintain a bullish outlook with price targets ranging from $61 to $136. For deeper insights into CYTK’s financial health and access to exclusive Pro Research Reports covering 1,400+ US stocks, visit InvestingPro. In other recent news, Cytokinetics has been the focus of several analyst updates following its fourth-quarter results and the launch of its drug, Myqorzo. Analysts from BofA Securities described the company’s fourth-quarter results as largely uneventful, maintaining a Neutral rating but slightly raisi...
Read full article at source